Maravai LifeSciences (MRVI) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
CORRECTION: Maravai Lifesciences Reports Second Quarter 2022 Financial Results
August 4, 2022 4:51 PM EDTSAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, August 4th, by Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), please note that a variety of changes have been made throughout the release. These includes the wording of the subheadline, the wording and figure in the fourth bullet point,  the wording and figures in the last paragraphs of each Financial Results section, and the Explanatory Notes numbers (9) and (10). The corrected release follows:
Maravai Lifesciences Reports Second Quarter 2022 Financial Results
... More


